Sennosides Tablet
NDC Package 51114-0225-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Sennosides tablets is sennosides are used to treat constipation. This formulation utilizes a tablet delivery system. Marketed by Vovantis Laboratories Private Limited, this product is identified by NDC 51114-0225.

Identification & Billing

NDC Package Code
51114-0225-1
Package Description
1000 TABLET in 1 POUCH
Product Code
51114-0225
11-Digit Billing Format
51114022501

Clinical Specifications

Proprietary Name
Sennosides
Non-Proprietary Name
Sennosides
Substance Name
Sennosides
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Active Ingredient(s)
SENNOSIDES 8.6 mg/1
Usage Information
Sennosides are used to treat constipation. They may also be used to clean out the intestines before a bowel examination/surgery. Sennosides are known as stimulant laxatives. They work by keeping water in the intestines, which causes movement of the intestines.

Regulatory & Marketing

Labeler Name
Vovantis Laboratories Private Limited
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
02-28-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51114-0225-1 identifies a specific commercial package of 1000 tablet in 1 pouch of Sennosides (UNFINISHED drug), drug for further processing labeled by Vovantis Laboratories Private Limited. This tablet is formulated for use and contains sennosides as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vovantis Laboratories Private Limited on February 28, 2022. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Sennosides are used to treat constipation. They may also be used to clean out the intestines before a bowel examination/surgery. Sennosides are known as stimulant laxatives. They work by keeping water in the intestines, which causes movement of the intestines.

How is this Vovantis Laboratories Private Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51114022501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51114-0225-1
11-Digit CMS (5-4-2)
51114-0225-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.